Eupraxia Pharmaceuticals Inc. (EPRX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Eupraxia Pharmaceuticals Inc. (EPRX) closed at USD 6.77 on 2026-10-15, a change of +24.4 % over the past year, with a market capitalization of USD 437.41M.

Eupraxia Pharmaceuticals Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Eupraxia Pharmaceuticals Inc. key figures

Previous close

USD 6.77 (2026-10-15)

1-year change

+24.4 %

Market cap

USD 437.41M

Enterprise value

USD 332.4M

P/E ratio (trailing)

-6.49

P/E ratio (forward)

-6.38

EPS (trailing)

-1.02

EPS (forward)

-1.04

PEG ratio

n/a

Price to book

4.26

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

10.71

Employees

49

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Eupraxia Pharmaceuticals Inc. and compare it with other stocks.